Roswell Park receives $7.7M for biobank

Hemokine modulatory regimen shows promise for TNBC in phase I study

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

November 22, 2024

Vol.50 No.44

In Brief

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Thomas Schwaab was named Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research institute.

September 13, 2024

Vol.50 No.34

In Brief

John Ashton named associate director for shared resources at Wilmot Cancer Institute

John M. Ashton, associate professor in the department of biomedical genetics, has been promoted from assistant director to associate director of shared resources at the University of Rochester’s Wilmot Cancer Institute.

September 13, 2024

Vol.50 No.34

In Brief

Roswell Park earns “exceptional” rating from NCI with best-ever core grant

Roswell Park Comprehensive Cancer Center has earned the highest—”exceptional”—rating from NCI as part of renewal of the grant the institution has held since 1972.

June 14, 2024

Vol.50 No.24

In Brief

Angela Yoon named director of MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource

Angela J. Yoon was named director of the MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource, effective Dec. 1; she will oversee a growing collection of cancer-associated biospecimens that allow researchers to translate Biological discoveries into prevention, diagnosis and treatment of cancer.

December 08, 2023

Vol.49 No.45

In Brief

Roswell Park to open $98M cell and gene therapy manufacturing facility

Roswell Park Comprehensive Cancer Center will open a $98 million cell and gene therapy manufacturing facility. It will be the first cell and gene therapy hub in New York.

October 20, 2023

Vol.49 No.39

Roswell Park receives $7.7M for biobank

YOU MAY BE INTERESTED IN

Hemokine modulatory regimen shows promise for TNBC in phase I study

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

John Ashton named associate director for shared resources at Wilmot Cancer Institute

Roswell Park earns “exceptional” rating from NCI with best-ever core grant

Angela Yoon named director of MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource

Roswell Park to open $98M cell and gene therapy manufacturing facility

Renew today!

Subscriber content

Never miss an issue!

Login